I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Small Molecule
Drug Discovery by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Small Molecule Drug
Discovery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 3: World 15-Year Perspective for Small Molecule Drug
Discovery by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Central Nervous
System by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Central Nervous System by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Central Nervous System
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Anti-Infective by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 14: World Historic Review for Anti-Infective by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Anti-Infective by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Immunological by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Immunological by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Immunological by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Other Therapeutic
Areas by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 20: World Historic Review for Other Therapeutic Areas by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Other Therapeutic Areas
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Target
Id/Validation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 23: World Historic Review for Target Id/Validation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Target Id/Validation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Hit Generation
and Selection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 26: World Historic Review for Hit Generation and
Selection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 27: World 15-Year Perspective for Hit Generation and
Selection by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Lead
Identification by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Lead Identification by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Lead Identification by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Lead Optimization
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 32: World Historic Review for Lead Optimization by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 33: World 15-Year Perspective for Lead Optimization by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 34: USA Current & Future Analysis for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Small Molecule Drug Discovery
by Therapeutic Area - Oncology, Central Nervous System,
Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Small Molecule Drug Discovery
by Process Phase - Target Id/Validation, Hit Generation and
Selection, Lead Identification and Lead Optimization Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

CANADA
Table 40: Canada Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

JAPAN
Table 46: Japan Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

CHINA
Table 52: China Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 53: China Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: China 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 55: China Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

EUROPE
Table 58: Europe Current & Future Analysis for Small Molecule
Drug Discovery by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Small Molecule Drug
Discovery by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Small Molecule Drug
Discovery by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 61: Europe Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 62: Europe Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Europe 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 64: Europe Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

FRANCE
Table 67: France Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: France Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: France 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 70: France Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 71: France Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 72: France 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

GERMANY
Table 73: Germany Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 74: Germany Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Germany 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 76: Germany Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Germany Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Germany 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

ITALY
Table 79: Italy Current & Future Analysis for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: Italy Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 81: Italy 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 82: Italy Current & Future Analysis for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 83: Italy Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Italy 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 85: UK Current & Future Analysis for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: UK Historic Review for Small Molecule Drug Discovery
by Therapeutic Area - Oncology, Central Nervous System,
Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: UK 15-Year Perspective for Small Molecule Drug
Discovery by Therapeutic Area - Percentage Breakdown of Value
Sales for Oncology, Central Nervous System, Cardiovascular,
Anti-Infective, Immunological and Other Therapeutic Areas for
the Years 2012, 2020 & 2027

Table 88: UK Current & Future Analysis for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 89: UK Historic Review for Small Molecule Drug Discovery
by Process Phase - Target Id/Validation, Hit Generation and
Selection, Lead Identification and Lead Optimization Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 90: UK 15-Year Perspective for Small Molecule Drug
Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

REST OF EUROPE
Table 91: Rest of Europe Current & Future Analysis for Small
Molecule Drug Discovery by Therapeutic Area - Oncology, Central
Nervous System, Cardiovascular, Anti-Infective, Immunological
and Other Therapeutic Areas - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Rest of Europe Historic Review for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Small Molecule
Drug Discovery by Therapeutic Area - Percentage Breakdown of
Value Sales for Oncology, Central Nervous System,
Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas for the Years 2012, 2020 & 2027

Table 94: Rest of Europe Current & Future Analysis for Small
Molecule Drug Discovery by Process Phase - Target
Id/Validation, Hit Generation and Selection, Lead
Identification and Lead Optimization - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 95: Rest of Europe Historic Review for Small Molecule
Drug Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 96: Rest of Europe 15-Year Perspective for Small Molecule
Drug Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

ASIA-PACIFIC
Table 97: Asia-Pacific Current & Future Analysis for Small
Molecule Drug Discovery by Therapeutic Area - Oncology, Central
Nervous System, Cardiovascular, Anti-Infective, Immunological
and Other Therapeutic Areas - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 98: Asia-Pacific Historic Review for Small Molecule Drug
Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Asia-Pacific 15-Year Perspective for Small Molecule
Drug Discovery by Therapeutic Area - Percentage Breakdown of
Value Sales for Oncology, Central Nervous System,
Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas for the Years 2012, 2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for Small
Molecule Drug Discovery by Process Phase - Target
Id/Validation, Hit Generation and Selection, Lead
Identification and Lead Optimization - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 101: Asia-Pacific Historic Review for Small Molecule Drug
Discovery by Process Phase - Target Id/Validation, Hit
Generation and Selection, Lead Identification and Lead
Optimization Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Small Molecule
Drug Discovery by Process Phase - Percentage Breakdown of Value
Sales for Target Id/Validation, Hit Generation and Selection,
Lead Identification and Lead Optimization for the Years 2012,
2020 & 2027

REST OF WORLD
Table 103: Rest of World Current & Future Analysis for Small
Molecule Drug Discovery by Therapeutic Area - Oncology, Central
Nervous System, Cardiovascular, Anti-Infective, Immunological
and Other Therapeutic Areas - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 104: Rest of World Historic Review for Small Molecule
Drug Discovery by Therapeutic Area - Oncology, Central Nervous
System, Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Rest of World 15-Year Perspective for Small Molecule
Drug Discovery by Therapeutic Area - Percentage Breakdown of
Value Sales for Oncology, Central Nervous System,
Cardiovascular, Anti-Infective, Immunological and Other
Therapeutic Areas for the Years 2012, 2020 & 2027

Table 106: Rest of World Current & Future Analysis for Small
Molecule Drug Discovery by Process Phase - Target
Id/Validation, Hit Generation and Selection, Lead
Identification and Lead Optimization - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and_x000D